The Indian Patent Office has revoked Novartis’ patent on its blockbuster cardiac drug, Vymada, reshaping the country’s ₹550-crore market for this therapy. The decision paves the way for generic competition, likely slashing prices by over 70% and dramatically improving access for India’s vast cardiovascular patient population.
Vymada’s Market Presence and Growth
Vymada, one of the most important cardiology drugs globally, accounts for 2.4% of India’s ₹23,000-crore cardiac drug segment. The therapy has been growing at an impressive 37% annually, reflecting strong clinical adoption and rising demand.
“Vymada holds a significant presence in India, with sales of around ₹550 crore,” said Nilaya Varma, Group CEO and Co-Founder of Primus Partners.
Generics Ready to Enter Market
More than 15 leading Indian pharmaceutical companies will launch generic versions within the next two to three months after the patent revocation. Prices, currently ranging between ₹650 and ₹700 per strip, will fall sharply.
“Intense competition from generics will likely drive prices down by more than 60 per cent over the next year,” Varma added.
Patent Office Cites Lack of Novelty
In its ruling, the Patent Office stated that Novartis’ patent lacked novelty and technical advancement. The company, it said, failed to demonstrate enhanced therapeutic efficacy or comparative benefits of its supramolecular complex over earlier disclosures. The office invoked Section 3(d) of the Indian Patent Act—the same clause used in 2013 to deny Novartis a patent for its cancer drug Glivec.
Legal Challenges and Industry Pushback
Over the years, generic makers such as Natco, Torrent Pharma, MSN Labs, and Eris Lifesciences faced legal restraints after Novartis’ actions, even as some launched products “at risk.” In a rare collaborative move, the Indian Pharmaceutical Alliance, along with IPCA and Micro Labs, opposed the patent at the post-grant stage, raising concerns over evergreening.
Impact on Prices and Patient Access
As reported by Business Standard, analysts expect the Indian market to witness an aggressive wave of competition. According to Nirali Shah, Pharma Analyst at Ashika Group, “Initial generic launches may come at a slight premium, but competition will drive a 50–70% price correction over the next 12–18 months. This will significantly expand patient access while normalising returns for manufacturers.”
A Shift Towards Affordability
While Novartis is likely to challenge the ruling, industry watchers believe this decision signals a strong shift towards affordability in one of India’s fastest-growing therapeutic areas. The influx of generics is expected to transform treatment accessibility for millions of cardiovascular patients.